Headquartered in Mountain View, CA·Fiscal year ends September·NYSE: ANRO·altoneuroscience.com
About Alto Neuroscience
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, including depression, schizophrenia and related conditions. It uses its proprietary Precision Psychiatry Platform to guide drug development and patient selection.
Its lead program, ALTO-207, is in late-stage development for treatment-resistant depression. ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, and ondansetron, a 5-HT3 receptor antagonist. The combination is designed to allow higher pramipexole doses with faster titration by reducing nausea and vomiting. It is being studied in the PACE program:
- PACE-1: Phase 2b, adjunctive TRD.
- PACE-2: planned Phase 3, adjunctive TRD.
- PACE-3: planned Phase 3, monotherapy TRD.
The pipeline also includes ALTO-300, in a Phase 2b trial in major depressive disorder, and ALTO-100, in a Phase 2b trial in bipolar depression. The company has no product revenue and funds operations through equity financings. It had approximately $319.8 million in cash, cash equivalents and restricted cash as of September 30, 2026, which it expects to fund planned operations through 2030. Updated
A $319.8 million cash pile now funds Alto Neuroscience through 2030, which means the clinical-stage depression developer can run its ALTO-207 Phase 3 monotherapy and adjunctive trials in parallel without another raise. Four data readouts land before 2H 2027, starting with FDA Phase 3 design feedback around year end.
Are you looking for low-cost stocks to add to your portfolio? Doing so can be a challenge. After all, stocks that trade with low share prices are often risky investment opportunities. That’s…
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, including depression, schizophrenia and related conditions. It uses its proprietary Precision Psychiatry Platform to guide drug development and patient selection.
What is the ANRO stock price target?
The Wall Street consensus 12-month price target for ANRO is $38.67.